Condition: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia · Relapsed or Refractory B Cell Non-Hodgkin Lymphoma · Sponsor: Autolus Limited
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Hodgkin lymphoma (B NHL).
This description comes directly from the study's public registry record.
Autolus Ltd · +44 (0) 203 911 4385 · clinicaltrials@autolus.com
Always discuss trial participation with your own doctor first.
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| Methodist Children's Hospital | San Antonio, Texas, United States | Recruiting |
| Primary Children's Hospital | Salt Lake City, Utah, United States | Recruiting |
| Hospital Vall d'Hebron | Barcelona, Spain | Recruiting |
| Hospital Nino Jesus | Madrid, Spain | Recruiting |
| Great Ormond Street Hospital for Children NHS Foundation Trust | London, United Kingdom | Recruiting |
| Royal Manchester Children's Hospital | Manchester, United Kingdom | Recruiting |
| Great North Children's Hospital | Newcastle upon Tyne, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06173518